In a patient with severe scalp psoriasis and a strong family history of atrial fibrillation, will biologic therapy prevent a psoriasis flare if a beta‑blocker is required in the future?

Will Biologics Prevent Psoriasis Flare if Beta-Blockers Are Needed?

Biologics will not prevent a beta-blocker-induced psoriasis flare, but they can effectively treat scalp psoriasis regardless of beta-blocker use—and importantly, the evidence does not support avoiding beta-blockers in psoriasis patients.

The Beta-Blocker and Psoriasis Controversy

The relationship between beta-blockers and psoriasis is far less clear-cut than commonly believed:

• Long-term use (≥6 years) showed a modest association with psoriasis development (OR 1.39,95% CI 1.11-1.73) in one nurse cohort study 1
• However, a larger UK study found no association between antihypertensive agents including beta-blockers and psoriasis (OR 0.9,95% CI 0.8-1.0) 1
• The guideline conclusion is definitive: "the preponderance of the evidence does not support the avoidance of particular antihypertensive medications (β-blockers, calcium-channel blockers, or others) in patients with psoriasis" 1

The proposed mechanism involves beta-blockers decreasing intracellular cAMP levels, affecting keratinocyte proliferation and granulocyte function 2, but this remains theoretical.

Your Patient's Specific Situation

Given your patient has:

• Severe scalp psoriasis
• Strong family history of atrial fibrillation (which increases their personal AF risk 3, 4)
• Potential future need for beta-blockers

The algorithmic approach should be:

1. Do NOT avoid beta-blockers if medically indicated for AF or other cardiovascular conditions—the evidence does not support this restriction 1

2. Initiate or optimize biologic therapy NOW for the severe scalp psoriasis, independent of beta-blocker considerations:

   • Infliximab or ustekinumab show the greatest efficacy for scalp psoriasis, with 94.3% and 94.9% PSSI improvement at 48 weeks respectively 5
   • Anti-IL-17 and anti-IL-23 agents demonstrate the highest clinical performance for scalp psoriasis 6
   • All biologics (infliximab, etanercept, adalimumab, ustekinumab) are recommended for moderate-to-severe scalp psoriasis 7

3. Monitor closely if beta-blockers are started, but expect the biologic to maintain disease control

Critical Caveats

• Biologics treat existing psoriasis; they are not prophylactic agents against drug-induced flares. There is no evidence that pre-treatment with biologics prevents beta-blocker-associated worsening
• The psoriasis-AF connection matters more than the beta-blocker concern: Your patient's psoriasis itself increases AF risk (HR 1.28,95% CI 1.20-1.36), with severe psoriasis showing even higher risk (HR 1.32) 3. This shared inflammatory mechanism (IL-6, IL-17, TNF-alpha) 4 means controlling the psoriasis with biologics may actually reduce cardiovascular risk
• If beta-blockers worsen psoriasis despite biologics, consider alternative antihypertensive classes rather than stopping the biologic

Bottom Line

Treat the severe scalp psoriasis aggressively with biologics now 7, 5. If beta-blockers become necessary for AF, use them—the evidence supports their safety in psoriasis patients 1. The biologic should maintain disease control, and if breakthrough occurs, intensify the biologic regimen rather than avoiding necessary cardiac medications.